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Abstract: 
	   The purpose of my research project has been to determine the nature of the 
binding relationship between caveolin and hFSHR inside sex cells. FSH plays a role in 
the maturation of these cells, and interfering with the receptor’s interaction with caveolin 
would prevent cell maturation (down regulating fertility). It is believed the interaction 
occurs through transmembrane domain IV of the receptor due to its aromatic nature. The 
treatment of sex cells with synthetic peptides that mimic the hFSHR-caveolin binding 
sequence should prevent the interaction, shutting down the signaling cascade from 
hFSHR. This can be tested for by the monitoring of downstream signals given off by 
hFSHR, including the presence (or absence) of phosphorylated p44, PKA, and CREB. It 
is hypothesized the wildtype peptide treatment will down regulate all of these signals 
when compared to the mutant control. Current data points towards this hypothesis 
holding true, with successful western blots displaying a noted difference in cell signaling 
between the wildtype and mutant peptide treatments. These results indicate the key 
interaction between caveolin and hFSHR likely occurs at transmembrane domain IV. 	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Introduction: 	  	   Follicle stimulating hormone (FSH) plays an important role in the maturation of 
sex cells in both males and females. FSH is part of the hypothalamic-pituitary-gonadal 
axis in both males and females [1]. Upon proper stimulation, the hypothalamus sends a 
signal to the anterior pituitary gland to release FSH. Its receptor, Human Follicle 
Stimulating Hormone Receptor (hFSHR), is only expressed in sex cells. In females, 
hFSHR is located in granulosa cells, found in the ovaries. A proper interaction between 
the hormone and its receptor in ovarian cells produces estrogen, allowing proper oocyte 
development. In males, the receptor is located in sertoli cells in the testis; a proper 
interaction promotes spermatogenesis [2]. 
 hFSHR is a G-Protein Couple Receptor (GPCR). It requires activation by an 
agonist to pass an extracellular signal to the intracellular proteins targeted. Upon binding 
an appropriate agonist, a GPCR’s alpha subunit exchanges a GDP for a GTP, becoming 
active. It then frees up both beta and gamma subunits, allowing those to pass on signals 
as well. A successful signal transduction cascade requires this activation mechanism to 
work perfectly, with all members in the right place at the right time.  
 hFSHR is not readily found on the surface of these cells. It is located in the 
cytosol, and requires the assistance of caveolin to be brought to the cellular membrane. 
This is accomplished through a caveolin binding motif in transmembrane domain IV in 
the receptor. Caveolin, a protein found in the caveolae of the cell membrane, has been 
proven to transport receptors to the cell surface before. Caveolae are a set of lipid rafts 
with a structure that allows them to bind and transport many cell receptors. The binding 
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of hFSHR is believed to be accomplished by an interaction of transmembrane domain IV 
of hFSHR with the caveolin protein [3]. 
 Any interference with this caveolin-hFSHR interaction would effectively silence 
the normally observed effects of FSH in sex cell maturation. Inversely, any up regulation 
of this interaction would allow for increased maturation ability in sex cells that struggle 
to mature by themselves. It is apparent this interaction can be affected either in the hopes 
of silencing sex cell maturation (down regulating fertilitiy), or over expressing this 
interaction (up regulating fertility).  
 A successful hFSHR signal cascade manifests itself in the appearance of 
downstream signal transduction, most notably due to the activation of adenylyl cyclase, 
producing Cyclic AMP that is bound by Protein Kinas A to activate the protein, which in 
turn activates a multitude of downstream enzymes. Two of the most important 
downstream signaling enzymes of this cascade are p44 Map Kinase and Cyclic-AMP 
response element binding protein (CREB), as seen in Figure 1. Both of these are 
phosporylated (activated) when there is a successful interaction of hFSHR with caveolin, 
allowing the receptor to come to the cell surface and bind its substrate, FSH. Therefore, 
monitoring the presence of activated p44 and activated CREB is an extremely effective 
method of determining if there has been a disruption event in the caveolin-hFSHR 
binding interaction.  
It has been shown in previous 
research projects that this 
critical binding motif can be 
blocked by the introduction of 
Figure 1. Current model for hFSHR signaling. 
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synthetic peptides with the same aromatic caveolin-binding motif as hFSHR. This was 
noted through monitoring the amount of phosphorylated CREB in cells after treatment 
with two different synthetic peptide memetics. A decrease in the amount of 
phosphorylated CREB was observed after treatment with the wildtype binding memetic 
when compared to the control, a mutant peptide with non-aromatic residues in the 
binding motif range. There was, however, no testing for the effects of these peptides on 
the amount of phosphorylated p44. This may in fact be a better indicator of the caveloin-
hFSHR interaction interference, as fewer upstream molecules can activate p44 compared 
to CREB. In other words, CREB can be activated by a multitude of mechanisms, so any 
drop in its activation could be a result of peptide interference with other activators of 
CREB.  
In order to allow the peptides to enter the cells, they are attached to a truncated 
version of the Tat protein found in HIV. This protein allows the virus to pass through cell 
membranes; it is used here to get the peptides through experimental cell membranes. The 
truncated Tat used also does not change peptide folding due to its incredibly charged 
nature; it truly is just a vector used to allow peptide entrance [4]. 
 The sequences of these peptides are shown in Figure 2. The important residues 
are the aromatic amino acids in red. In the wild type peptide, the red residues include the 
same aromatic residues as those found in the aforementioned transmembrane domain; 
these are changed to non-aromatic residues in the mutant peptide (as shown by those 
residues put in bold print). 
 
  
Tat (Blue)-WT Caveolin binding motif (Red) 
YGRKKRRQRRRFAFAAALFPIF 
 
YGRKKRRQRRRLALAAALLPIL 
Tat (Blue)-Mutant Caveolin binding motif 
(Red)	  	  
Figure	  2	  Custom	  Peptides	  used	  in	  previous	  research.	  	  Their	  
sequences	  in	  italics	  are	  from	  the	  tat	  peptide.	  	  The	  
remainder	  of	  the	  sequence	  is	  from	  hFSHR	  amino	  acids	  479-­‐
489.	  	  Mutated	  residues	  are	  shown	  in	  bold. 
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The wildtype peptide should be able to bind easily to the caveolin in the cell and 
shutdown the signal cascade. If this occurs, hFSHR would be unable to to bind to its 
substrate, as it would not be at the surface of the cell. This would result in a decrease in 
the activation of CREB and of p44. The mutant peptide, on the other hand, won’t be able 
to bind to caveolin in the cell and should not affect the amount of signaling caused by 
hFSHR.  
The primary antibody used in my experiment is Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) Antibody #9101, with a secondary antibody Goat anti-Rabbit IgG 
(H+L) Secondary Antibody, HRP conjugate #65-6120. The advantage of using Phospho-
p44/42 MAPK antibody 9101 is its specificity for phosphorylated p44 MAP Kinase. It 
does not cross react with phosphorylated residues of either JNK/SAPK or p38 MAP 
Kinase, and does not cross-react with non-phosphorylated Erk1/2. This allows for better 
results in the experiment.  
My hypothesis is the cell samples treated with the wildtype peptide should show 
marked differences in signaling compared to those treated with the mutant peptide.  
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Methods: 
A method developed by Roh et. Al [5] was adapted for use in this experiment.  
Cell Culture 
 HEK 293R cells were used in this experiment due to their stable expression of the 
desired receptor. Cells were grown in the Union College tissue culture room in sterile 
conditions and split at 90% confluence to prepare them for the peptide treatments. 
 
Peptide Treatments 
 Previously prepared stock solution of both wildtype and mutant peptides were 
used at concentrations of 10-mM. Three 15mL conical tubes had 10 µL of WT, mutant, 
or no peptide added to 10mL of serum free medium. Then, two milliliters of each mixture 
was added to the appropriate well in two different 6-well dishes. The layout of these 
treatments is outlined in Figure 4. Peptide treatments lasted an hour for the cells, allowing 
them to affect the HEK293R cells in the wells.  
 
Treatment with FSH 
 4.8 µL of hFSH was mixed into 1.2mL of SFM to create the stock treatment 
solution while the peptide incubation was occurring. Once the peptide treatment was 
over, the media in the 6-well dishes was sucked off and replaced with 4mL of fresh SFM 
to ensure no peptide residue remained. 100µL of the prepared hFSH stock solution was 
added to the appropriate wells in the dishes as outlined in Figure 5. Incubation took place 
for periods of 30, 15, 5 and zero minutes to see how signaling changes over time with the 
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treatments. Once the desired time had elapsed, the media was aspirated off the cells to 
remove any lingering hFSH.  
 
Cellular Extractions 
 Immediately following media aspiration, the dishes were placed on ice and each 
well underwent two washes with 1mL of freezing PBS. In order to lyse open the cells, a 
solution of lysis buffer was created. One phosSTOP tablet and one cOmplete tablet were 
added to 10mL of lysis buffer and 500µL of this mixture was added to each well and 
incubated for 20 minutes. The phoSTOP tablet prevents depshosphorylation of 
phosphorylated proteins (the data to be examined) and the cOmplete tablet prevented 
those proteins from being cleaved by proteases (4,5). The well contents were then 
scraped into twelve microfuge tubes on ice (contents detailed in Table 1). The contents of 
each tube were transferred into a dounce homegnizer, dounced to ensure all cells had 
been lysed open, then returned to their microfuge tube. After all cells had been dounced, 
the tubes were centrifuged at maximum speed for ten minutes with the supernatants 
collected and placed into different microfuge tubes (Table 2).  
 
BCA Assay 
 To determine the concentrations of protein in each cell sample, a bicinchoninic 
acid protein assay was performed. 10 µL of eight standards of pre-determined 
concentrations were loaded in triplicate on the appropriate 96 well-microplate. The 
unknown samples were also added in incriments of 10µL in triplicate to the 
corresponding wells on the plate reader. Once all standards and samples had been loaded, 
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a working reagent was prepared from the BCA kit at 50:1 ratio of A to B. 200µL of this 
reagent was pippeted into each well to help with protein determination. A plastic cover 
was placed on top of the microplate, and it was placed in an incubator at 37C for a half 
hour. After this incubation period, the plate was loaded into the appropriate assay reader 
and a standard curve was created. The samples were compared to the curve by the assay 
to determine their average protein content (from the standard curve). This information 
was printed out and used to standardize all samples to the lowest concentration sample, 
diluting the extremely concentrated samples. This allowed for the creation of evenly 
concentrated samples, as not to incorrectly read a signal as having a stronger reaction to 
FSH when it was due to the higher level of protein in the sample. Gel samples had a total 
volume of 200µL, with up to 100µL of sample and the remainder filled in by 2X SDS 
buffer. These samples were boiled at 70C for 30 minutes once prepped and then frozen 
for later usage. 
 
Gel Electrophoresis 
 3.5 mL of 10% SDS-polyacrlyamide resolving gel was added to each gel 
apparatus, covered in isopropyl alcohol and allowed to sit for an hour to set. Once the 
hour was up, the isopropyl was poured out, and a 4% SDS-polyacrylamide stacking gel 
was used to fill the rest of the apparatus with  a 10 well comb placed in the gel and 
allowed to set for 30 minutes. The comb was removed once the gel was set to create the 
loading wells for the samples. 20µL of a protein molecular weight marker was added in 
the first well of each gel ran, with the aforementioned prepared gel samples added (20 
µL) to the appropriate wells to analyze the amount of signaling the specific well had 
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undergone. The gels were then run at 60-65 minutes at 100 volts for one hour in prepared 
1X electrophoresis buffer.  
 
Western Blotting 
 In order to visualize the results of the gel electrophoresis step, a western blot was 
performed. Gels were removed from the glass plates and soaked in transfer buffer for 
fifteen minutes. In order to transfer the gels, six separate Watmen filter papers were cut 
for each gel at 3.25X2 inch measurements, with one nitrocellulose membrane for each gel 
also cut to that size. The membranes were dipped in methanol and soaked in transfer 
buffer for 10 minutes. Once the gels and membranes had been soaked for the appropriate 
amounts of time, “sandwiches” were made: 3 of the Watman filter papers dipped briefly 
in transfer buffer, the membrane, the gel, and 3 more Watman filter papers on top. This 
set-up was then run on a semi-wet transfer cell apparatus for 15 minutes at 15 volts to 
pass the proteins from the gel to the membrane. Once the transfer was complete, the 
membranes were soaked in 5% milk in 1XTBST for 60 minutes for blocking in a sealed 
bag. 
While blocking occurred, solutions of primary antibodies were prepared. The 
antibodies used were” P-p44 to detect phosphorylated p44 MAPK, P-CREB to detect 
phosphorylated CREB and P-PKA to detect phosphorylated PKA proteins. The standard 
concentration was 5µL of antibody to 10mL of 5%BSA in 1XTBST. At the end of the 
blocking period, the membranes were placed in new bags with the appropriate primary 
antibody and left to soak in them overnight in the Wold cold room. The next day, 
solutions of secondary antibody were prepped with the standard concentration being 5µL 
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of antibody to 10mL of 5% milk. The membranes were then removed from their primary 
antibody bags, washed 3 times for 5 minutes in 1XTBST before being placed in new bags 
with the appropriate secondary antibody for another hour long incubation. At the end of 
this incubation, the membranes were removed from the bags, washed in 1X TBST for 3 
sets of 5 minutes each, then soaked in Thermo Scientific SuperSignal® West Pico 
Chemiluminescent Substrate for 5 minutes to develop an image of the transferred 
proteins. The membranes were then photographed with the BioRad ImageLab and 
analyzed for protein expression.  
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Results: 
 
 
Figure 3. Western Blot of peptide and hormone treatments. Antibody used was for proteins 
phosphorylated by Protein Kinase A. CIM peptide is the wildtype peptide, non-cim is the mutant peptide.  
 
The western blot shown in Figure 3 shows a clear difference in signaling between 
cell samples treated with  the wildtype peptide, and those treated with the mutant peptide. 
There is very little downstream phosphorylation of proteins by PKA in the wildtype 
peptide until the 15 minute mark. This strong signal falls off at the 30 minute mark. The 
mutant peptide reaches a maximum signal at the 5 minute mark, 10 minutes faster than 
the wildtype peptide. This signal proceeds to tail off both the 15 and 30 minute mark. The 
maximum signal for the mutant peptide (5 minute mark) is larger than the maximum 
signal for the wildtype peptide treatment (15 minute mark). There is a clear difference in 
the signaling patterns, both in timing and intensity, as anticipated in the hypothesis. 
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Figure 4. Western Blot for peptide and hormone treatments. Antibody used was anti-phospho-p44 
 The western blot in figure 4 shows a difference in timing and level of activation 
of P44 between the mutant and wildtype peptides. The wildtype peptide treatments show 
almost no signaling for the first 3 time points. It only begins to appear at the 30-minute 
mark, with the maximum occurring after a half hour of FSH stimulation. The mutant 
peptide treatments show a maximum occurring at the 15-minute time point, continuing 
over into the 30 minute time point, There is almost no signal for the mutant peptide for 
the first two time points. Again, there is clearly a difference between the level and timing 
of activation of P44 in cell samples treated with either the wildtype or mutant peptides.  
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  CIM	  	  	  	  	  	  	  	  	  	  CIM	  	  	  	  	  	  	  	  	  	  	  CIM	  	  	  	  	  	  	  	  	  	  	  	  	  CIM	  	  	  	  	  	  	  	  Non-­‐CIM	  	  	  Non-­‐CIM	  	  	  	  	  	  Non-­‐CIM	  	  	  	  Non-­‐CIM	  	  	  	  	  	  MW	  	  	  	  	  	  	  	  	  0	  min.	  	  	  	  	  	  	  	  5	  min.	  	  	  	  	  15	  min	  	  	  	  	  	  30	  min	  	  	  	  	  	  	  	  	  0	  min	  	  	  	  	  	  	  	  	  5	  min	  	  	  	  	  	  	  	  	  	  15	  min	  	  	  	  	  	  	  	  30	  min	  	  	  	  	  	  Marker	  
	   14	  
Discussion: 
 The results from this experiment support my hypothesis. Beginning with a 
detailed observation of Figure 3, there is a clear difference in signaling between the 
wildtype peptide treated cell samples and those treated with the mutant peptide. Again, 
the wildtype peptide shares the theorized aromatic amino acid residues believed to exist 
in the caveolin-hFSHR motif (transmembrane domain IV). The interruption of 
downstream signaling from PKA shows there has been interference with the hFSHR in 
these cells. This is likely, although not certainly, due to a binding interaction occurring 
between caveolin and the wildtype peptides that have entered the cell. This binding 
prevents the downstream signaling from taking place in the cells. The mutant peptide 
treatment serves as the control for the monitoring of proteins phosphorylated by PKA, so 
any difference noted between wildtype and mutant supports the hypothesis. There is a 
clear difference; therefore the wildtype peptide must have interfered with the signaling, 
most likely by binding to caveolin and preventing the receptor from reaching the surface. 
 The results in Figure 4 also support the hypothesis of the experiment. There is a 
clear difference in the timing and level of activation of P44 in the cells treated with either 
wildtype or mutant peptide. This is again likely caused by an interference with caveolin-
hFSHR localization when cells are treated with the wildtype peptide that is able to bind 
with the caveolin.   
While my results are limited in scope, similar experiments with similar outcomes 
have been performed before. The possibility that the wildtype peptide is able to interfere 
with the direct interaction of caveolin with the GPCR is supported in a study done by 
Kim et Al [6]. They examined the interaction of the mGlu-1 receptor (a GPCR) with 
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caveolin through the use of both “blocking” and “mutant” peptides. The blocking peptide 
had the aromatic amino acid residues theorized to mediate the binding between caveolin 
and the receptor, while the mutant peptide had non-aromatic amino acids at those 
residues. Upon separate co-immunoprecipitation experiments of both caveolin and mGlu 
receptor, it was clear they did not associate in cells treated with the blocking peptide. The 
peptide treatment was preventing the binding of the receptor to caveolin when it 
contained the aromatic amino acid residues, similar to my experiment. Further 
experimentation showed this interference with the binding interaction between caveolin 
and the receptor prevented its localization to lipid rafts. This was accomplished through 
peptide treatments and double-labeling immunocytochemistry of endogenous mGlu1α 
receptor and lipid rafts. There were again significant differences in the localization of the 
receptor in lipid rafts between blocking and non-blocking peptides. All of these data 
together support a receptor-caveolin interaction being key for the receptor to become 
localized in lipid rafts. mGlu-1 receptor is a GPCR, like hFSHR, and this similarity 
shows a related mechanism is likely occurring in my experiment. 
Experimental data produced by Bhatanger, et Al., also supports a proposed 
interaction between caveolin and GPCRs [7]. Instead of using peptide treatments to 
interfere with the theorized interaction between GPCRs and caveolin, the researchers 
used siRNA to knockdown the expression of caveolin in a variety of cell lines, most 
notably C6 glioma cells, that expressed both 5-HT(2A) and Galpha(q)-coupled P2Y 
purinergic receptor. Prior to the knockdowns, co-immunoprecipitation studies showed the 
caveolin was associating with the receptors in control cell lines. This of course shows 
there is an interaction between caveolin and the GPCRs in the cells and is an experiment 
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that should be performed on hFSHR in the future. Knockouts took place after this first 
experiment proved the interaction existed. The cells with knocked out caveolin showed 
decreased cell signaling from both GPCRs when compared to control cell lines with 
normal levels of caveolin expressed in them. This data was gathered by measuring cell 
signaling with calcium flux assays in the cells after knockdowns occurred. The results of 
this experiment further support the conclusion that there is likely an interaction between 
GPCRs and caveolin that is critical to the function of the receptors. The cells were unable 
to pass on signals from those receptors after caveolin was eliminated from the cells, 
showing caveolin to be related to their function. Although this experiment did not 
investigate where that interaction was taking place on the receptor, its data still supports 
the results from my peptide treatment experiments.  
The evidence in the literature and in my experiment points to supporting a 
caveolin-GPCR binding interaction to localize to lipid rafts in cell membranes. In the 
case of hFSHR, this is important for a multitude of reasons mentioned before. The 
primary field affected by a proper study of the hFSHR-caveolin interaction is fertility [5]. 
The ability of a drug to interfere with the hFSHR-caveolin interaction motif would 
revolutionize contraception treatments. Current drugs that serve as birth control are 
commonly taken in pill form and involve the use of synthetic estrogen and progestin [8]. 
They aren’t quite 100% effective, especially when the drug regimen isn’t followed 
strictly. Hormone imbalances can occur, and improvements can definitely be made in the 
design of these drugs. 
 This is exactly where a drug that is able to interfere with the hFSHR-caveolin 
interaction would be a lifesaver. It wouldn’t require synthetic hormone treatments; it 
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would theoretically simply prevent the maturation of sex cells in both men and women. A 
birth control treatment for both sexes would revolutionize how we view contraception, 
with reproductive responsibility not just falling on the shoulders of women if this 
treatment came to fruition. Given that spermatogenesis and follicular development both 
require a successful signaling cascade from hFSH, preventing the receptor from reaching 
the surface would allow the body to produce normal levels of FSH without any sex cell 
maturation. This type of silver bullet treatment is still far down the road, but there is 
promise in interfering with hFSHR-caveolin interactions. The data gathered in this 
experiment and in the literature shows a decrease in GPCR downstream signaling when 
cell samples are treated with peptides designed to block the aforementioned interaction. 
However, there are issues with duration of treatment in the experiment. Even the 
wildtype peptide inhibitor lost its effect between 15 and 30 minutes and normal signaling 
returned. This could be due to the production of new receptors or new caveolin, or a 
binding affinity issue with the peptide to the caveolin (i.e. it isn’t that strong and 
eventually dissociates). There needs to be more data gathered on the ability of a drug to 
block out caveolin-hFSHR binding in sex cells, but this potential drug target would be 
fantastic. It would eliminate the requirement for synthetic hormone treatments and keep 
the same efficacy as current drug treatments if not improve upon it.  
 The idea of creating a drug treatment for birth control that would simply prevent 
hFSHR from being brought to the surface is sound in logic but still far down the road 
from being realized. There needs to be a multitude of other studies performed to confirm 
the localization of hFSHR in lipid rafts is a direct result of its interaction with caveolin. If 
there were a different mechanism used by the cell to bring the receptor to the lipid rafts at 
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the surface that is also blocked by the peptide, then the data above are false positives. The 
first study needs to of course first be replication of the western blots to confirm 
downstream signaling is affected by the peptide treatments and it was not experimental 
error. The next step after this would be co-immunoprecipitating caveolin in both peptide 
treatments and seeing if the peptide is binding to it, or if the receptor is still able to bind 
to the caveolin. If the wildtype peptide were found to be binding to caveolin, it would 
confirm that the aromatic amino acid residues at transmembrane domain IV of the 
hFSHR are almost certainly binding to caveolin to be transported to lipid rafts in the cell 
surface. This would prove the binding motif is critical for hFSHR function, and open a 
new door for a potentially longer lasting drug treatment in blocking the receptor from 
being brought to the surface of the cell.  
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